Introduction: The causative agents of acute tonsillopharyngitis are viruses and bacterial flora. Treatment of acute pharyngitis is mainly local, which includes aerosols with antiseptics. Aim: Study of antimicrobial action of "Apicold oral spray" on clinical isolates of microorganisms Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Candida albicans isolated from patients' oropharynx in patients. Material and methods: The effect of Apicold Oral Spray (manufactured by APIPHARMA doo) on clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Candida albicans in Ukrainian patients was studied. Antimicrobial activity was assessed after 5, 10 and 20 minutes of action of one dose of "Apicold oral spray" on microorganisms. Bactericidal and fungicidal action (inhibition of cell growth of microorganisms) is expressed as a percentage according to the control. Results and discussion: Apicold Oral Spray has a 100% antimicrobial effect after 5 minutes on clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Candida albicans (complete growth inhibition of all 5 clinical isolates after 20 minutes). Conclusion: "Apicold oral spray" has a high antimicrobial effect on clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Candida albicans, which is confirmed by 100% inhibition of the growth of all bacteria after 5 minutes
Введение. Различными формами риносинуситов страдает до 15 взрослого населения и 5 детского населения планеты. Причиной острого риносинусита являются различные вирусы и бактерии. Цель. Изучение антимикробного действия Апиколд Пропо, спрей назальный на клинические изоляты микроорганизмов, которые являются наиболее частыми возбудителями острого бактериального синусита в Украине. Материалы и методы. Исследовали действие медицинского изделия Апиколд Пропо, спрей назальный (производитель АПИФАРМА д.о.о.) на клинические изоляты микроорганизмов Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa (2 штамма дикого типа и госпитальный) и Candida albicans, выделенных из носа больных пациентов. Антимикробная активность оценивалась через 5, 10 и 20 минут действия дозой медицинского изделия на микроорганизмы. Бактерицидное и фунгицидное действие (угнетение роста клеток микроорганизма на чашках Петри) выражается в процентах в соответствии с контролем. Результаты и обсуждение. Апиколд Пропо, спрей назальный имеет 100-ное антимикробное действие на клинический изолят Moraxella catarrhalis через 5 минут, 100-ное антимикробное действие на клинический изолят Streptococcus pneumonia через 20 минут, 99-ное антимикробное действие на клинический изолят Haemophilus influenza через 20 минут, 48,7-ное фунгицидное действие на штамм Candida albicans через 20 минут. Апиколд Пропо, спрей назальный имеет 65,7-ное антимикробное действие на клинический изолят Pseudomonas aeruginosa, wild type через 20 минут. Отсутствует антимикробное действие Апиколд Пропо, спрей назальный на госпитальный штамм Pseudomonas aeruginosa, который имеет резистентность к большинству антибиотиков. Выводы. Апиколд Пропо, спрей назальный имеет антимикробное действие на клинические изоляты Moraxella catarrhalis, Streptococcus pneumonia (100), Haemophilus influenza (99), клинический изолят Pseudomonas aeruginosa, wild type (65,7), фунгицидное действие на штамм Candida albicans (48,7). Отсутствует антимикробное действие медицинского изделия в отношении госпитального штамма Pseudomonas aeruginosa, который является резистентным к большинству антибиотиков. Introduction. Various forms of rhinosinusitis affect up to 15 of the adult population and 5 of childrens population in the world. The cause of acute rhinosinusitis is a variety of viruses and bacteria. Purpose. The study the antimicrobial effect of Apicold Propo, nasal spray on clinical isolates of microorganisms that are the most common causative agents of acute bacterial sinusitis in Ukraine. Materials and methods. There was studied the effect of Apicold Propo, nasal spray (producer APIFARMA d.o.o.) on clinical isolates of the microorganisms Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa (2 strains of wild type and hospital type) and Candida albicans isolated from nose of sick patients. Antimicrobial activity was evaluated in 5, 10 and 20 minutes of exposure. Bactericidal and fungicidal action (inhibition of the growth of microorganism cells on Petri dishes) is expressed as a percentage in accordance with the control. Results and discussion. Apicold Propo, nasal spray has 100 antimicrobial effect on the clinical isolate of Moraxella catarrhalis in 5 minutes, 100 antimicrobial effect on the clinical isolate of Streptococcus pneumonia in 20 minutes, 99 antimicrobial effect on the clinical isolate of Haemophilus influenza in 20 minutes, 48.7 fungicidal effect on Candida albicans strain in 20 minutes. Apicold Propo nasal spray has 65.7 antimicrobial effect on the clinical isolate Pseudomonas aeruginosa (wild type) in 20 minutes. There is no antimicrobial effect of Apicold Propo, nasal spray on the hospital strain Pseudomonas aeruginosa, which has resistance to the majority of antibiotics. Conclusions. Apicold Propo, nasal spray has antimicrobial effect on clinical isolates of Moraxella catarrhalis, Streptococcus pneumonia (100), Haemophilus influenza (99), clinical isolate Pseudomonas aeruginosa of wild type (65,7), fungicidal effect on Candida albicans strain (48,7). There is no antimicrobial effect on the hospital strain of Pseudomonas aeruginosa, which is resistant to the majority of antibiotics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.